AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 179 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $424,000 | -30.1% | 56,621 | -15.3% | 0.00% | 0.0% |
| Q1 2022 | $607,000 | +2.4% | 66,814 | -21.2% | 0.00% | 0.0% |
| Q4 2021 | $593,000 | -41.7% | 84,737 | -5.2% | 0.00% | -50.0% |
| Q3 2021 | $1,018,000 | -29.1% | 89,398 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $1,435,000 | +57.0% | 89,699 | +75.3% | 0.00% | 0.0% |
| Q1 2021 | $914,000 | -34.6% | 51,172 | -50.5% | 0.00% | -33.3% |
| Q4 2020 | $1,397,000 | +147.7% | 103,462 | +115.2% | 0.00% | +200.0% |
| Q3 2020 | $564,000 | -95.8% | 48,075 | -87.2% | 0.00% | -96.7% |
| Q4 2018 | $13,542,000 | -46.5% | 375,935 | -8.5% | 0.03% | -37.5% |
| Q3 2018 | $25,310,000 | +26.2% | 410,888 | +38.2% | 0.05% | +14.3% |
| Q2 2018 | $20,062,000 | +26.7% | 297,290 | +1.9% | 0.04% | +55.6% |
| Q1 2018 | $15,833,000 | -24.0% | 291,856 | -13.2% | 0.03% | -22.9% |
| Q4 2017 | $20,827,000 | +10.3% | 336,202 | -13.5% | 0.04% | +9.4% |
| Q3 2017 | $18,889,000 | +54.5% | 388,666 | +67.1% | 0.03% | +45.5% |
| Q2 2017 | $12,223,000 | +958.3% | 232,610 | +813.5% | 0.02% | +1000.0% |
| Q1 2017 | $1,155,000 | -36.2% | 25,464 | -46.9% | 0.00% | -50.0% |
| Q4 2016 | $1,810,000 | – | 47,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |